- From: Eric Prud'hommeaux <eric@w3.org>
- Date: Tue, 21 Jan 2014 10:08:04 -0500
- To: public-semweb-lifesci@w3.org, Charlie Mead <charles.normanmead@gmail.com>, Claude Nanjo <cnanjo@gmail.com>, Josh Mandel <jmandel@gmail.com>, Hans Constandt <hans@ontoforce.com>, Christel Daniel <christel.daniel@crc.jussieu.fr>, 'Sajjad Hussain' <sajjad.hussain@crc.jussieu.fr>, Mustafa Yuksel <mustafa@srdc.com.tr>, Gokce Banu Laleci Erturkmen <gokce@srdc.com.tr>, Erick Von Schweber <erick@surveyorhealth.com>, "Solbrig, Harold R." <Solbrig.Harold@mayo.edu>, Stan Huff <Stan.Huff@imail.org>, "Jiang, Guoqian, M.D., Ph.D." <Jiang.Guoqian@mayo.edu>, "Emory Fry (Google Drive)" <eafry@gmx.com>, Conor Dowling <conor-dowling@caregraf.com>, David Booth <david@dbooth.org>, Arash Shaban-Nejad <arash.shaban-nejad@mail.mcgill.ca>, Michael Denny <msdenny@mitre.org>, Kerstin Forsberg <kerstin.l.forsberg@gmail.com>, hong.sun@agfa.com, jakub.kozak@collite.cz, suat@srdc.com.tr, a.j.g.gray@hw.ac.uk, Frank.van.Harmelen@cs.vu.nl, annette@cs.vu.nl
<http://www.w3.org/2014/01/14-hcls-minutes>
[1]W3C
COI call
14 Jan 2014
See also: [2]IRC log
Attendees
Present
ericP, +1.919.767.aaaa, TimWilliams, Mike_Denny,
Kerstin_Forsberg, charlie, Sajjad, claude
Regrets
Chair
SV_MEETING_CHAIR
Scribe
ericP
Contents
* [3]Topics
1. [4]FDA Therapeutic Area strawman
* [5]Summary of Action Items
__________________________________________________________________
FDA Therapeutic Area strawman
<scribe> scribenick: ericP
-> [6]http://www.w3.org/2013/12/FDA-TA/ strawman
charlie_: FDA said the focus on the TA work is efficacy points
... obsevations connecting intervention and pathophysioly
... obs: normal, outcomes, endpoints
<kerstin> Charlie talking through
[7]http://www.w3.org/2013/12/FDA-TA/TA-MetaModel-cmap.png
charlie_: metamodel is the above model
ericP: bottom-up abuse of the metamodel, coopted for base classes
-> [8]http://www.w3.org/2014/Talks/0107-FDA-TA-egp/#(4)
[9]http://www.w3.org/2014/Talks/0107-FDA-TA-egp/#(2)
[10]http://www.w3.org/2014/Talks/0107-FDA-TA-egp/#(2)
Claude: i think of observations as quantitative measurements and the
thing i do the make the observations
... unless obs really means the act of observing, and the result is
captured elsewhere, this model is potentally confusing
... coulld separate the act of observing from the data observed
charlie_: in early RIM, there was a separation. now Obs is a kind of
Act with a code.
... RIM has substance administration etc.
... FDA cares about processes as measured by some generic idea of the
value of the obs
Claude: i'm working on models for CDS
charlie_: FDA is not trying to feed CDS, instead just looking at the
evidence around effectiveness of intervention
Claude: we're looking at a CDS ontology, could we interop with this?
charlie_: we asked that it all be sharable, but note that this will be
narrow
ericP: is the distinction useful in CDS?
Claude: HL7's model for CDS is the Virtual Medical Record
... a CDS rule might look at a set of characteristics about a patient
and fire off a diagnostic procedure
Sajjad: have you written formal dens?
charlie_: FDA knows they have to do it
-> [11]http://www.w3.org/2013/12/FDA-TA/ strawman
ericP: can two people use variations of a ontology and get useful data
interop
[12]http://www.w3.org/2014/Talks/0107-FDA-TA-egp/
-> [13]http://www.w3.org/2013/12/FDA-TA/ strawman
charlie: expect ta-specific, ta-group (e.g. commonalities at organ
level or systemic processes like inflamation), and pan-ta
... we need to show FDA that common semantics across TAs will be
recognizable
Mike: Q: about Obs -[ AtomicObs, OutcomeAssessment ]
-> [14]http://www.w3.org/2013/12/FDA-TA/subject-amy.ttl amy gets better
# Positive outcome
:subjectsKidneyGraftWithNormalFunction a
rrej:KidneyGraftOutcomeAssessment ; # a rrej:GraftSurvival ;
mm: hasObservationTime "2013-10-19T12:34:00Z"^^xsd:dateTime ;
... beforeIntervention :subjectsOutpatientGFR10 , :subjectsGFRpreOp ;
... intervention :subjectOnExcipiens , :subjectsTransplant ;
... afterIntervention :subjectsPostOpDay5GFR ;
... hasOutcomeValue rrej:NormalFunctioningGraft .
Claude: re-usable in the clinical practice feedback loop
charlie_: determining efficacy of interventions may well require the
granularity that Claude alluded to before.
Summary of Action Items
[End of minutes]
__________________________________________________________________
Minutes formatted by David Booth's [15]scribe.perl version 1.138
([16]CVS log)
$Date: 2014-01-14 17:06:27 $
__________________________________________________________________
Scribe.perl diagnostic output
[Delete this section before finalizing the minutes.]
This is scribe.perl Revision: 1.138 of Date: 2013-04-25 13:59:11
Check for newer version at [17]http://dev.w3.org/cvsweb/~checkout~/2002/scribe/
Guessing input format: RRSAgent_Text_Format (score 1.00)
Found ScribeNick: ericP
Inferring Scribes: ericP
Default Present: ericP, +1.919.767.aaaa, TimWilliams, Mike_Denny, Kerstin_Forsbe
rg, charlie, Sajjad, claude
Present: ericP +1.919.767.aaaa TimWilliams Mike_Denny Kerstin_Forsberg charlie S
ajjad claude
WARNING: No meeting title found!
You should specify the meeting title like this:
<dbooth> Meeting: Weekly Baking Club Meeting
WARNING: No meeting chair found!
You should specify the meeting chair like this:
<dbooth> Chair: dbooth
Got date from IRC log name: 14 Jan 2014
Guessing minutes URL: [18]http://www.w3.org/2014/01/14-hcls-minutes.html
People with action items:
[End of [19]scribe.perl diagnostic output]
References
1. http://www.w3.org/
2. http://www.w3.org/2014/01/14-hcls-irc
3. http://www.w3.org/2014/01/14-hcls-minutes#agenda
4. http://www.w3.org/2014/01/14-hcls-minutes#item01
5. http://www.w3.org/2014/01/14-hcls-minutes#ActionSummary
6. http://www.w3.org/2013/12/FDA-TA/
7. http://www.w3.org/2013/12/FDA-TA/TA-MetaModel-cmap.png
8. http://www.w3.org/2014/Talks/0107-FDA-TA-egp/#(4)
9. http://www.w3.org/2014/Talks/0107-FDA-TA-egp/#(2)
10. http://www.w3.org/2014/Talks/0107-FDA-TA-egp/#(2)
11. http://www.w3.org/2013/12/FDA-TA/
12. http://www.w3.org/2014/Talks/0107-FDA-TA-egp/
13. http://www.w3.org/2013/12/FDA-TA/
14. http://www.w3.org/2013/12/FDA-TA/subject-amy.ttl
15. http://dev.w3.org/cvsweb/~checkout~/2002/scribe/scribedoc.htm
16. http://dev.w3.org/cvsweb/2002/scribe/
17. http://dev.w3.org/cvsweb/~checkout~/2002/scribe/
18. http://www.w3.org/2014/01/14-hcls-minutes.html
19. http://dev.w3.org/cvsweb/~checkout~/2002/scribe/scribedoc.htm
--
-ericP
office: +1.617.599.3509
mobile: +33.6.80.80.35.59
(eric@w3.org)
Feel free to forward this message to any list for any purpose other than
email address distribution.
There are subtle nuances encoded in font variation and clever layout
which can only be seen by printing this message on high-clay paper.
Received on Tuesday, 21 January 2014 15:08:41 UTC